Akeso Biopharma of Zhongshan Closes $45 Million B Round

Akeso Biopharma, a Zhongshan antibody company, closed a $45 million B round, led by the GTJA Investment Group. Founded in 2012, Akeso subjects its antibody candidates to 3D analysis simulations. It says the process improves the antibody's affinity for a target by a factor of up to 100 times. Two years ago, Merck/MSD agreed to a $200 million package of milestones in return for global rights to an Akeso immune checkpoint antibody. Akeso is currently developing 25 research projects involving drugs for oncology, inflammation, autoimmune and cardiovascular diseases. More details.... Share this with colleagues: // //